SlideShare uma empresa Scribd logo
1 de 23
Joris Veltman (onderzoeker)
Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
Het probleem; Ineffectieve medicijnen!
1953
Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59  TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1  TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ?        OF   	Fout in aantal chromosomen?
Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
Genoomdiagnostiek in 2015  DNA ? Genoomsequentie < 1 uur < 500 euro
Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en  Bioinformatica expertise! Totale genoomsequentie 1 individu
ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
NRC 13 feb 2010
Personal genomics en impact op geneeskunde
Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen  verschillen
Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
THANK YOU !
NEXT

Mais conteúdo relacionado

Mais procurados

Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Fundación Ramón Areces
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesOncos Therapeutics
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrpPrasad CSBR
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Institut Pasteur de Madagascar
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantationspa718
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry ReviseAnaliese Wenger
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 ZincfingerRyla Best
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...People with Multiple Sclerosis (Vic) Inc.
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assaysnanog
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphismSimon Silvan
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)Freya Cardozo
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olingeramandacturner
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsBorlaug Global Rust Initiative
 

Mais procurados (19)

Qpcr
QpcrQpcr
Qpcr
 
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
Dra. Carmen Espinós - 'Neuropatías periféricas hereditarias'
 
Present and future of oncolytic virus therapies
Present and future of oncolytic virus therapiesPresent and future of oncolytic virus therapies
Present and future of oncolytic virus therapies
 
7 immunology-csbrp
7 immunology-csbrp7 immunology-csbrp
7 immunology-csbrp
 
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. Santos Manes - Simposio Internacional 'Terapias oncológicas avanzadas'
 
PNAS 1992 FBH.PDF
PNAS 1992 FBH.PDFPNAS 1992 FBH.PDF
PNAS 1992 FBH.PDF
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
 
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise2015 Detection of Leishmania Parasites via Flow Cytometry Revise
2015 Detection of Leishmania Parasites via Flow Cytometry Revise
 
2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides2009 09 08 Wiltshire Ipit Seminar Slides
2009 09 08 Wiltshire Ipit Seminar Slides
 
Seminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling systemSeminar 08-10-2008 - wnt signaling system
Seminar 08-10-2008 - wnt signaling system
 
CCR5 Zincfinger
CCR5 ZincfingerCCR5 Zincfinger
CCR5 Zincfinger
 
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...Fingolimod  the path from a fungal metabolite to fda approved drug-biom255-sp...
Fingolimod the path from a fungal metabolite to fda approved drug-biom255-sp...
 
Jc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc AssaysJc Rethinking Of Hsc Assays
Jc Rethinking Of Hsc Assays
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
HPV vaccine (UID198612)
HPV vaccine (UID198612)HPV vaccine (UID198612)
HPV vaccine (UID198612)
 
ProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene OlingerProImmune Antigen Characterization Summit Gene Olinger
ProImmune Antigen Characterization Summit Gene Olinger
 
NK Immunodeficiencies
NK ImmunodeficienciesNK Immunodeficiencies
NK Immunodeficiencies
 
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild TetraploidsSources of Stem Rust Resistance in Cultivated and Wild Tetraploids
Sources of Stem Rust Resistance in Cultivated and Wild Tetraploids
 

Semelhante a Joris Veltman

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe FroguelAssociation LIR
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Sherman Jia
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...Simon Gemble
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013Elsa von Licy
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosMauricio Lema
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Fundación Ramón Areces
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013Elsa von Licy
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases European School of Oncology
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDNYU FACES
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumEAFO1
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptxEllyanaFarina1
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Thermo Fisher Scientific
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Fundación Ramón Areces
 

Semelhante a Joris Veltman (20)

04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel04 rencontres biomédicale LIR Philippe Froguel
04 rencontres biomédicale LIR Philippe Froguel
 
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
Genome sequencing uncovers MS phenocopies in primary progressive multiple scl...
 
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
The TRK to Tumor-Agnostic Care in Solid Tumors: A Pathology-Focused Guide to ...
 
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
2011 - Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 tr...
 
Cancer regulators 2013
Cancer regulators 2013Cancer regulators 2013
Cancer regulators 2013
 
Paneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidosPaneles genómicos en tumores sólidos
Paneles genómicos en tumores sólidos
 
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias' Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
Dra. Mary Reilly - 'Neuropatías periféricas hereditarias'
 
Apoptosis
ApoptosisApoptosis
Apoptosis
 
Cancer drug targets 2013
Cancer drug targets 2013Cancer drug targets 2013
Cancer drug targets 2013
 
Diaz-Arrastia, Ramon
Diaz-Arrastia, RamonDiaz-Arrastia, Ramon
Diaz-Arrastia, Ramon
 
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
ABC1 - L. van't Veer - Genomic signatures of specific sites of metastases
 
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
The Promise of New Concepts and Innovative Therapy in Advanced Sarcoma: From ...
 
Tuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MDTuberous Sclerosis - Orrin Devinsky, MD
Tuberous Sclerosis - Orrin Devinsky, MD
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptx
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
Oncomine Cancer Research Panel (OCP) | ESHG 2015 Poster PS12.131
 
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'Stephan Zuckner - 'Neuropatías periféricas hereditarias'
Stephan Zuckner - 'Neuropatías periféricas hereditarias'
 

Mais de UMC St Radboud (20)

Astrid Hartendorf
Astrid HartendorfAstrid Hartendorf
Astrid Hartendorf
 
Annet van Betuw
Annet van BetuwAnnet van Betuw
Annet van Betuw
 
Floortje Agema
Floortje AgemaFloortje Agema
Floortje Agema
 
Arjan Broers
Arjan BroersArjan Broers
Arjan Broers
 
Yvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen FokkeYvonne Engels en Jeroen Fokke
Yvonne Engels en Jeroen Fokke
 
Marjolein Roes
Marjolein RoesMarjolein Roes
Marjolein Roes
 
Erich Taubert
Erich TaubertErich Taubert
Erich Taubert
 
Geert Klein Breteler
Geert Klein BretelerGeert Klein Breteler
Geert Klein Breteler
 
Erik Jansen
Erik JansenErik Jansen
Erik Jansen
 
Irene Muller
Irene MullerIrene Muller
Irene Muller
 
Joia Stoutjesdijk
Joia StoutjesdijkJoia Stoutjesdijk
Joia Stoutjesdijk
 
Sietske van der Veldt
Sietske van der VeldtSietske van der Veldt
Sietske van der Veldt
 
Ellen van Bodegom
Ellen van BodegomEllen van Bodegom
Ellen van Bodegom
 
Saskia Timmer
Saskia TimmerSaskia Timmer
Saskia Timmer
 
Rob Speekenbrink
Rob SpeekenbrinkRob Speekenbrink
Rob Speekenbrink
 
Jaco van Duivenbode
Jaco van DuivenbodeJaco van Duivenbode
Jaco van Duivenbode
 
Salmaan Sana
Salmaan SanaSalmaan Sana
Salmaan Sana
 
Bart Timmers
Bart TimmersBart Timmers
Bart Timmers
 
Martijn vd Eijk
Martijn vd EijkMartijn vd Eijk
Martijn vd Eijk
 
Michiel Sedelaar
Michiel SedelaarMichiel Sedelaar
Michiel Sedelaar
 

Último

Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGDSC PJATK
 
THE BEST IPTV in GERMANY for 2024: IPTVreel
THE BEST IPTV in  GERMANY for 2024: IPTVreelTHE BEST IPTV in  GERMANY for 2024: IPTVreel
THE BEST IPTV in GERMANY for 2024: IPTVreelreely ones
 
Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024Enterprise Knowledge
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...FIDO Alliance
 
PLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. StartupsPLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. StartupsStefano
 
IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIES VE
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCzechDreamin
 
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)Julian Hyde
 
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdfHow Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdfFIDO Alliance
 
The UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, OcadoThe UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, OcadoUXDXConf
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty SecureFemke de Vroome
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsUXDXConf
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfFIDO Alliance
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...FIDO Alliance
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlPeter Udo Diehl
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfFIDO Alliance
 
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...CzechDreamin
 
Powerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara LaskowskaPowerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara LaskowskaCzechDreamin
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераMark Opanasiuk
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyJohn Staveley
 

Último (20)

Google I/O Extended 2024 Warsaw
Google I/O Extended 2024 WarsawGoogle I/O Extended 2024 Warsaw
Google I/O Extended 2024 Warsaw
 
THE BEST IPTV in GERMANY for 2024: IPTVreel
THE BEST IPTV in  GERMANY for 2024: IPTVreelTHE BEST IPTV in  GERMANY for 2024: IPTVreel
THE BEST IPTV in GERMANY for 2024: IPTVreel
 
Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024
 
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
Secure Zero Touch enabled Edge compute with Dell NativeEdge via FDO _ Brad at...
 
PLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. StartupsPLAI - Acceleration Program for Generative A.I. Startups
PLAI - Acceleration Program for Generative A.I. Startups
 
IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
Measures in SQL (a talk at SF Distributed Systems meetup, 2024-05-22)
 
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdfHow Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
How Red Hat Uses FDO in Device Lifecycle _ Costin and Vitaliy at Red Hat.pdf
 
The UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, OcadoThe UX of Automation by AJ King, Senior UX Researcher, Ocado
The UX of Automation by AJ King, Senior UX Researcher, Ocado
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty Secure
 
Strategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering TeamsStrategic AI Integration in Engineering Teams
Strategic AI Integration in Engineering Teams
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdfLinux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
Linux Foundation Edge _ Overview of FDO Software Components _ Randy at Intel.pdf
 
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
SOQL 201 for Admins & Developers: Slice & Dice Your Org’s Data With Aggregate...
 
Powerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara LaskowskaPowerful Start- the Key to Project Success, Barbara Laskowska
Powerful Start- the Key to Project Success, Barbara Laskowska
 
Intro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджераIntro in Product Management - Коротко про професію продакт менеджера
Intro in Product Management - Коротко про професію продакт менеджера
 
Demystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John StaveleyDemystifying gRPC in .Net by John Staveley
Demystifying gRPC in .Net by John Staveley
 

Joris Veltman

  • 2. Personalized genomic medicine Joris Veltman j.veltman@antrg.umcn.nl www.genomicdisorders.nl
  • 5. Het humane genoom receptenboek voor leven 6 miljard bouwstenen 2001
  • 6.
  • 7. NIJMEGEN INTERNATIONALE EXPERT ERFELIJKE ZIEKTEN VCAN CFH CHM USH2Aisob RPGRIP1 TECTA NDP EHMT1 EYS MYCN FXYD2 DFNB59 TSPAN12 ABCA4 CDH7 ESRRB P63 LARGE PDE6C SETBP1 RPGRIP1L OFD1 17Q21 LRTOMT TKS4 IKAROS MAOA SS18/SSX CEP290 SENP1/MESDC2 ZNF674 CNTNAP2 GRXCR1 TET2 CRB1 PRPS1 TBX4 RPGR TRPN L1/L2 LCA5 ROR2 EPCAM COL4A3
  • 8. Complexiteit genonderzoek beperkt klinische impact! Fout in bouwstenen DNA ? OF Fout in aantal chromosomen?
  • 9. Genomics wordt spotgoedkoop! Kosten in kaart brengen 1 genoom
  • 10. Genoomdiagnostiek in 2015 DNA ? Genoomsequentie < 1 uur < 500 euro
  • 11. Nijmegen investeert in genoomsequencing Roche, GS FLX Titanium Since 11-2008 Life Technologies, SOLiD Since 9-2009
  • 12. Van sequentie tot genoom:Veel puzzelwerk Miljoenen korte sequenties per individu Supercomputers en Bioinformatica expertise! Totale genoomsequentie 1 individu
  • 13. ACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAGTCGA ATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCACA CGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGA TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGCAAACGCACCG GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCCAACCAC GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGATCGA ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCG CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTACGATCG GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGAC GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCACT GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGCG ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGCT CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGA GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGGAC CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCATCG CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGA GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAATC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCCAC CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATTCGCGCGGGGGCAAACGCACCAACCACCACAGCGGGGGCAAAGGGGCCAA GCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAATCGATCGAAACGCAC ATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGCGCGCTCGGTGC CTAGCTAGCTAGCTACGATACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGAT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACG CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCAAGC CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCATTAGCTA CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAACG GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACCC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACTCGA CACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGAT TCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCCAACT GCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCT GCTAGCTAGCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGTCGT CACCAACCACCACAGTCGCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGGCAAACGCACCAACCACCACTCGCTA CAGTCGATCGATCGATCGATCGCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCAGCTAGCTAGCTC CCAACCACCACAGCGGGGGCAAAGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTAAGCT GCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACCACCACAGTCGATCGATCGATCGATCGCGCTCGCTAGCTAGCTACGC GCTACGATCGAATCGATCGATCGATCGCGCTCGCTAGCTAGCTAGCTACGATCGAACTCGCTCGCGCGGGGGCAAACGCACCAACACT
  • 14. NRC 13 feb 2010
  • 15. Personal genomics en impact op geneeskunde
  • 16. Waarom reageren mensen verschillend op medicijnen?Oftewel: Hoe verschillend zijn ze nu echt? 5,999 miljard overeenkomsten 1 miljoen verschillen
  • 17.
  • 18. Wie ben ik en wat zijn mijn gezondheidsrisoco’s? Hoe zit het bij mij?
  • 19.
  • 20. Een ander probleem; Recessieve ziekten Kans op dragerschap 1: 1000 Kans op dragerschap 1: 1000 Indien beide drager Dan kans van 1 op 4! Kans op ziekte 1: 4,000,000
  • 21. Personalizedmedicine and the role of genomics PERSONALIZED GENOMIC MEDICINE DE TOEKOMST VAN DE GENEESKUNDE!
  • 23. NEXT